Endomyocardial proteomic signature corresponding to the response of patients with dilated cardiomyopathy to immunoadsorption therapy

Journal of Proteomics

Volumn 150, Issue , 2017, Pages 121-129

  Bhardwaj, Gourav ^a,c   Dörr, Marcus ^a,c   Sappa, Praveen Kumar ^a   Ameling, Sabine ^a,c   Dhople, Vishnu ^a   Steil, Leif ^a   Klingel, Karin ^b   Empen, Klaus ^a   Beug, Daniel ^a   Völker, Uwe ^a,c   Felix, Stephan B ^a,c   Hammer, Elke ^a,c  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Dilated cardiomyopathy; Endomyocardial biopsies; Label free tandem mass spectrometry; Multiple reaction monitoring; Therapy response

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALGRANULIN A; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S; IMMUNOGLOBULIN G; KININOGEN; PERILIPIN 4; PROTEIN A; UNCLASSIFIED DRUG; AUTOANTIBODY; PROTEOME;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART FAILURE; HEART PROTECTION; HUMAN; HUMAN TISSUE; IMMUNOADSORPTION; IMMUNOREGULATION; LIPID METABOLISM; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; CARDIAC MUSCLE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; BIOMARKERS; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; MYOCARDIUM; PILOT PROJECTS; PROGNOSIS; PROTEOME; PROTEOMICS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84988447909     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2016.09.001     Document Type: Article

References (52)

1. [1] Maron, B.J., Towbin, J.A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006), 1807–1816.
2. [2] Manolio, T.A., Baughman, K.L., Rodeheffer, R., Pearson, T.A., Bristow, J.D., Michels, V.V., et al. Prevalence and etiology of idiopathic dilated cardiomyopathy. Am. J. Cardiol. 69 (1992), 1458–1466.
3. [3] Yajima, T., Knowlton, K.U., Viral myocarditis: from the perspective of the virus. Circulation 119 (2009), 2615–2624.
4. [4] Kandolf, R., Sauter, M., Aepinus, C., Schnorr, J., Selinka, H., Klingel, K., Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res. 62 (1999), 149–158.
5. [5] Kallwellis-Opara, A., Dörner, A., Poller, W., Noutsias, M., Kühl, U., Schultheiss, H., et al. Autoimmunological features in inflammatory cardiomyopathy. Clin. Res. Cardiol. 96 (2007), 469–480.
6. [6] Heymans, S., Hirsch, E., Anker, S.D., Aukrust, P., Balligand, J., Cohen-Tervaert, J.W., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11 (2009), 119–129.
7. [7] Jahns, R., Boivin, V., Schwarzbach, V., Ertl, G., Lohse, M.J., Pathological autoantibodies in cardiomyopathy. Autoimmunity 41 (2008), 454–461.
8. [8] Jahns, R., Boivin, V., Hein, L., Triebel, S., Angermann, C.E., Ertl, G., et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Investig. 113 (2004), 1419–1429.
9. [9] Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9 (2003), 1477–1483.
10. [10] Bulut, D., Scheeler, M., Niedballa, L.M., Miebach, T., Mügge, A., Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. Clin. Res. Cardiol. 100 (2011), 603–610.
11. [11] Felix, S.B., Staudt, A., Landsberger, M., Grosse, Y., Stangl, V., Spielhagen, T., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J. Am. Coll. Cardiol. 39 (2002), 646–652.
12. [12] Staudt, A., Schaper, F., Stangl, V., Plagemann, A., Bohm, M., Merkel, K., et al. Immunohistological changes in dilated cardiomyopathy induced by Immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 103 (2001), 2681–2686.
13. [13] Felix, S.B., Staudt, A., Dörffel, W.V., Stangl, V., Merkel, K., Pohl, M., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. J. Am. Coll. Cardiol. 35 (2000), 1590–1598.
14. [14] Knebel, F., Böhm, M., Staudt, A., Borges, A.C., Tepper, M., Jochmann, N., et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int. J. Cardiol. 97 (2004), 517–520.
15. [15] Schimke, I., Müller, J., Priem, F., Kruse, I., Schön, B., Stein, J., et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J. Am. Coll. Cardiol. 38 (2001), 178–183.
16. [16] Staudt, A., Staudt, Y., Hummel, A., Empen, K., Dörr, M., Trimpert, C., et al. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther. Apher. Dial. 10 (2006), 42–48.
17. [17] Bulut, D., Scheeler, M., Wichmann, T., Börgel, J., Miebach, T., Mügge, A., Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin. Res. Cardiol. 99 (2010), 633–638.
18. [18] Felix, S.B., Beug, D., Dörr, M., Immunoadsorption therapy in dilated cardiomyopathy. Expert. Rev. Cardiovasc. Ther. 13 (2015), 145–152.
19. [19] Staudt, A., Herda, L.R., Trimpert, C., Lubenow, L., Landsberger, M., Dörr, M., et al. Fcgamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin. Pharmacol. Ther. 87 (2010), 452–458.
20. [20] Trimpert, C., Herda, L.R., Eckerle, L.G., Pohle, S., Müller, C., Landsberger, M., et al. Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur. J. Clin. Investig. 40 (2010), 685–691.
21. [21] Staudt, A., Staudt, Y., Dörr, M., Böhm, M., Knebel, F., Hummel, A., et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004), 829–836.
22. [22] Ameling, S., Herda, L.R., Hammer, E., Steil, L., Teumer, A., Trimpert, C., et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur. Heart J. 34 (2013), 666–675.
23. [23] Aichler, M., Luber, B., Lordick, F., Walch, A., Proteomic and metabolic prediction of response to therapy in gastric cancer. World J. Gastroenterol. 20 (2014), 13648–13657.
24. [24] Shipitsin, M., Small, C., Choudhury, S., Giladi, E., Friedlander, S., Nardone, J., et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer 111 (2014), 1201–1212.
25. [25] He, J., Whelan, S.A., Lu, M., Shen, D., Chung, D.U., Saxton, R.E., et al. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. International Journal of Proteomics, 2011, 2011, 896476.
26. [26] Aebersold, R., Burlingame, A.L., Bradshaw, R.A., Western blots versus selected reaction monitoring assays: time to turn the tables?. Molecular and Cellular Proteomics 12 (2013), 2381–2382.
27. [27] Bluemlein, K., Ralser, M., Monitoring protein expression in whole-cell extracts by targeted label- and standard-free LC-MS/MS. Nat. Protoc. 6 (2011), 859–869.
28. [28] Chang, C., Picotti, P., Hüttenhain, R., Heinzelmann-Schwarz, V., Jovanovic, M., Aebersold, R., et al. Protein significance analysis in selected reaction monitoring (SRM) measurements. Molecular and Cellular Proteomics, 11, 2012 M111.014662.
29. [29] Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26 (2005), 1115–1140.
30. [30] Remme, W.J., Swedberg, K., Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22 (2001), 1527–1560.
31. [31] Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, John, J.V., Ponikowski, P., Poole-Wilson, P.A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure 10 (2008), 933–989.
32. [32] Staudt, A., Hummel, A., Ruppert, J., Dörr, M., Trimpert, C., Birkenmeier, K., et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. American Heart Journal, 152, 2006, 712.e1-6.
33. [33] Mahrholdt, H., Wagner, A., Deluigi, C.C., Kispert, E., Hager, S., Meinhardt, G., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 (2006), 1581–1590.
34. [34] Aretz, H.T., Myocarditis: the Dallas criteria. Hum. Pathol. 18 (1987), 619–624.
35. [35] Hammer, E., Goritzka, M., Ameling, S., Darm, K., Steil, L., Klingel, K., et al. Characterization of the human myocardial proteome in inflammatory dilated cardiomyopathy by label-free quantitative shotgun proteomics of heart biopsies. J. Proteome Res. 10 (2011), 2161–2171.
36. [39] Zhu, W., Smith, J.W., Huang, C., Mass spectrometry-based label-free quantitative proteomics. J. Biomed. Biotechnol., 2010, 2010, 840518.
37. [40] Dávila-Román, V.G., Vedala, G., Herrero, P., de las Fuentes, L., Rogers, J.G., Kelly, D.P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 40 (2002), 271–277.
38. [41] Ventura-Clapier, R., Garnier, A., Veksler, V., Energy metabolism in heart failure. J. Physiol. 555 (2004), 1–13.
39. 31P NMR and surface fluorometry study. Basic Res. Cardiol. 85 (1990), 342–357.
40. [43] Schulze, K., Becker, B.F., Schauer, R., Schultheiss, H.P., Antibodies to ADP-ATP carrier–an autoantigen in myocarditis and dilated cardiomyopathy–impair cardiac function. Circulation 81 (1990), 959–969.
41. [44] Chen, W., Chang, B., Wu, X., Li, L., Sleeman, M., Chan, L., Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice. Am. J. Physiol. Endocrinol. Metab. 304 (2013), E770–E779.
42. [45] Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., Dyck, J.R.B., Myocardial triacylglycerol metabolism. J. Mol. Cell. Cardiol. 55 (2013), 101–110.
43. [46] Dalen, K.T., Schoonjans, K., Ulven, S.M., Weedon-Fekjaer, M.S., Bentzen, T.G., Koutnikova, H., et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 53 (2004), 1243–1252.
44. [47] Sahoo, S.K., Kim, T., Kang, G.B., Lee, J., Eom, S.H., Kim, D.H., Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum. J. Biol. Chem. 284 (2009), 31109–31121.
45. [48] Campbell, D.J., The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 28 (2001), 1060–1065.
46. [49] Ma, L., Haugen, E., Ikemoto, M., Fujita, M., Terasaki, F., Fu, M., S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int. J. Cardiol. 155 (2012), 26–32.
47. [50] Averill, M.M., Kerkhoff, C., Bornfeldt, K.E., S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 223–229.
48. [51] Kim, H., Kang, H.J., Lee, H., Lee, S., Yu, M., Kim, H., et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. 8 (2009), 1368–1379.
49. [52] Katashima, T., Naruko, T., Terasaki, F., Fujita, M., Otsuka, K., Murakami, S., et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ. J. 74 (2010), 741–748.
50. [53] Raphael, R., Purushotham, D., Gastonguay, C., Chesnik, M.A., Kwok, W., Wu, H., et al. Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. J. Transl. Med., 14, 2016, 18.
51. [54] Boyd, J.H., Kan, B., Roberts, H., Wang, Y., Walley, K.R., S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ. Res. 102 (2008), 1239–1246.
52. [55] Tschoepe, C., Müller, I., Vogl, T., Pieske, B., van Linthout, S., Role of S100A8 and S100A9 alarmins in Coxsackievirus B3-induced myocarditis. J. Am. Coll. Cardiol., 67, 2016, 1398.